Podcast Episodes

Back to Search
Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecard
Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecard

Season 7 Episode 379

Argenx the tier-jumping European biotech, believes its proposed $2.2 billion purchase of Forte Biosciences will add a second multi-indication product…

3 months, 3 weeks ago

Short Long
View Episode
Ep. 378 - U.K. cabinet shuffle, Taiwan biotech and Biogen data
Ep. 378 - U.K. cabinet shuffle, Taiwan biotech and Biogen data

The departure of U.K. Science Minister Patrick Vallance is a blow for U.K. biotech. On the latest BioCentury This Week podcast, BioCentury’s analysts…

4 months ago

Short Long
View Episode
Ep. 377 - Trends in life sciences talent with CBRE's Ian Anderson
Ep. 377 - Trends in life sciences talent with CBRE's Ian Anderson

Season 7 Episode 377

After nearly three years of sluggish job growth, hiring is turning a corner in the U.S. life sciences industry, while the talent pool is expanding be…

4 months ago

Short Long
View Episode
Ep. 376 - M&A momentum: 3Q public markets preview
Ep. 376 - M&A momentum: 3Q public markets preview

Season 7 Episode 376

M&A enthusiasm is carrying biotech amid tepid reception for launches. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss BioCe…

4 months, 1 week ago

Short Long
View Episode
Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotech
Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotech

Season 7 Episode 375

Novartis is deepening its antibody-drug conjugate capabilities with its $1.1 billion acquisition of U.K. biotech Myricx Pharma. On the latest episode…

4 months, 2 weeks ago

Short Long
View Episode
Ep. 374 - Parkinson's deep dive & FDA trial reforms
Ep. 374 - Parkinson's deep dive & FDA trial reforms

Season 7 Episode 374

New Parkinson’s disease programs aim to move beyond the historical norm of symptom management, branching into targeted therapeutics and cell therapie…

4 months, 3 weeks ago

Short Long
View Episode
Ep. 373 - AbbVie M&A, FDA reversals, a CAR T first
Ep. 373 - AbbVie M&A, FDA reversals, a CAR T first

Season 7 Episode 373

AbbVie's $10.9 billion deal to acquire Apogee will expand its immunology pipeline by delivering assets for atopic dermatitis and asthma. On the lates…

4 months, 4 weeks ago

Short Long
View Episode
Ep. 372 - Biotech IPOs, Biosecure Act, cachexia pipeline
Ep. 372 - Biotech IPOs, Biosecure Act, cachexia pipeline

Season 7 Episode 372

Biotech IPOs that are getting out remain hot — but will that continue into the fall? On the latest BioCentury This Week podcast, BioCentury’s analyst…

5 months ago

Short Long
View Episode
Ep. 371 - Moving faster at the academia-industry interface
Ep. 371 - Moving faster at the academia-industry interface

Season 7 Episode 371

Getting into the clinic fast to de-risk assets has become the name of the game in biotech, and at the academia-industry interface, too.
From AI to NAM…

5 months, 1 week ago

Short Long
View Episode
Ep. 370 - Calmer waters for FDA; Servier, Lilly deals
Ep. 370 - Calmer waters for FDA; Servier, Lilly deals

Season 7 Episode 370

FDA’s new leadership is sailing the agency into calmer waters amid a search for a permanent commissioner and permanent center directors. On the lates…

5 months, 1 week ago

Short Long
View Episode

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us